Eiger Biopharmaceuticals' Bankruptcy Filing

By
Claudia Santos
1 min read

Eiger Biopharmaceuticals Inc., a company developing therapies for rare metabolic diseases, has filed for bankruptcy. Publicly traded Eiger listed about $38.8 million in assets and $53.1 million in liabilities in a Chapter 11 petition filed Monday in Dallas. The bankruptcy filing will give Eiger time to discuss restructuring options with its creditors. This decision reflects the challenges faced by Eiger in the current market environment and raises questions about the future of the company's innovative therapies. It remains to be seen how Eiger will navigate this difficult situation and whether it will be able to emerge from bankruptcy with a path forward for its groundbreaking treatments. The implications of this filing extend to stakeholders and investors, as they await developments and decisions that will shape the future of Eiger Biopharmaceuticals.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines.The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings